# A Study of ALKS 5461 for the Treatment of Major Depressive Disorder (MDD) - the FORWARD-3 Study

> **NCT02158546** · PHASE3 · COMPLETED · sponsor: **Alkermes, Inc.** · enrollment: 447 (actual)

## Conditions studied

- Major Depressive Disorder

## Interventions

- **DRUG:** ALKS 5461
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT02158546
- **Lead sponsor:** Alkermes, Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2014-05
- **Primary completion:** 2015-12
- **Final completion:** 2015-12
- **Target enrollment:** 447 (ACTUAL)
- **Last updated:** 2019-06-25


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02158546

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02158546, "A Study of ALKS 5461 for the Treatment of Major Depressive Disorder (MDD) - the FORWARD-3 Study". Retrieved via AI Analytics 2026-06-04 from https://api.ai-analytics.org/clinical/NCT02158546. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*